A Phase 1, First-in-human Study of VX-668

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.

Clinical Trial Description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05727800
Study type	Interventional
Source	Vertex Pharmaceuticals Incorporated
Contact
Status	Completed
Phase	Phase 1
Start date	February 8, 2023
Completion date	February 13, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02547532` - Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT00005292` - Alpha1-antitrypsin Deficiency Registry	N/A
Withdrawn	`NCT02900183` - Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels	Phase 2
Terminated	`NCT02502201` - Environment Effect on Six-Minute Walk Test Performance	N/A
Completed	`NCT01810458` - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Active, not recruiting	`NCT04262284` - Respreeza® Self-administration and Learning Program (AmAREtTI Study)
Recruiting	`NCT06186492` - A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)	Phase 1
Recruiting	`NCT06405633` - A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD	Phase 1/Phase 2
Completed	`NCT01054339` - Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency	Phase 2
Completed	`NCT03815396` - Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency	Phase 1
Completed	`NCT03008915` - Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency	Phase 2
Completed	`NCT01419158` - Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)	N/A
Recruiting	`NCT00500123` - The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Active, not recruiting	`NCT05643495` - A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype	Phase 2
Completed	`NCT02810327` - Alpha-1 Carrier Genomics Study
Terminated	`NCT02363946` - A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)	Phase 1
Completed	`NCT03804021` - Long-Term Follow-up Study of ADVM-043
Active, not recruiting	`NCT02014415` - Alpha-1 Antitrypsin Deficiency Adult Liver Study
Terminated	`NCT01241942` - Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability	N/A